2022-09-21| In-DepthSpecial

ESMO 2022: Promising Trials Highlights That Are Worth Following

by Elena Chen
Share To
This year's event, organized by the European Society for Medical Oncology (ESMO), took place in Paris from September 9 to 13. This congress is an oncology event for international HCPs, the majority from Europe. 

As the opening conference remarked, sustainability will be the heart of many discussions. “Sustainability is about maintaining important, high-quality processes over time. In oncology, seeing the rise in cancer cases, we need to ask ourselves how we can ensure the essential process of caring for patients can be maintained,” said ESMO President Prof. Solange Peters.

For cancers that are not currently avoidable, screening and early detection can both maximize individuals’ chances of survival and alleviate the burden on health systems by reducing the proportion of patients with advanced diseases who require costly, chronic therapies and care.  

This year has been a fructiferous year for oncologists, with many positive clinical trial results and upgrades from previous clinical trials. As many new drugs are ongoing, we’ll focus on those discussed most lately. 

It's free! Log in now to read

AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
Arsenal Biosciences Announced Another $70 million Collaboration, This Time With Genentech
Sciwind Biosciences And SynerK Join Forces To Develop siRNA Therapeutics
Acticor Enrolls First Patient in Phase 2/3 Stroke Treatment Study
Daiichi Sankyo Wins Approval For Cancer Treatment in Japan
Seagen Strikes Potential $650 million Deal with LAVA Therapeutics for Cancer Treatment
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!